Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According to DelveInsight

DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hepatic Encephalopathy Market Report:
• The Hepatic Encephalopathy market size was valued approximately USD 1,680 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, Germany held the largest market share among the EU4 and the UK, accounting for 31%, while Spain had the smallest share, representing 10%.
• In November 2024, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company utilizing its proprietary technology platform to enhance therapeutics via efficient oral delivery, announced the publication and discussion of a manuscript titled "Oral LPCN 1148 Improves Sarcopenia and Hepatic Encephalopathy in Male Patients with Cirrhosis: A Randomized, Placebo-Controlled Phase 2 Trial.
• In March 2024, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, has reported encouraging top-line findings from a Phase 2 clinical trial of LPCN 1148. LPCN 1148 is an oral candidate aimed at managing cirrhosis, focusing on preventing recurrence of OHE (hepatic encephalopathy) and treating sarcopenia. Positioned as a potential "First in Class" product candidate due to its novel mechanism of action (MOA), Lipocine intends to engage with the FDA to outline a pathway towards filing a New Drug Application (NDA).
• The total number of diagnosed prevalent cases of hepatic encephalopathy in the US is projected to rise significantly, with a notable compound annual growth rate (CAGR) by 2034, starting from approximately 209,000 cases in 2023.
• In 2023, the UK had the highest diagnosed prevalent population of hepatic encephalopathy among European countries, accounting for 28%, followed by Germany. Conversely, Spain had the lowest diagnosed prevalence, representing about 9% of hepatic encephalopathy cases that year.
• In Japan, the majority of diagnosed hepatic encephalopathy cases in 2023 were of covert hepatic encephalopathy, with approximately 17.7 thousand cases. Meanwhile, overt hepatic encephalopathy accounted for around 11.8 thousand cases during the same year.
• Key Hepatic Encephalopathy Companies: Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Health Americas, Inc., Ocera Therapeutics, Horizon Pharma, Mallinckrodt, and others
• Key Hepatic Encephalopathy Therapies: Xifaxan (Rifaximin/OHE7), Golexanolone, Rifaximin (SSD), AXA1665, GR3027 (Golexanolone), VE303, Rifaximin, AST-120, HPN-100, MNK6106, and others
• The Hepatic Encephalopathy epidemiology based on gender analyzed that out of the total diagnosed prevalent cases of Hepatic Encephalopathy, in the United States, 72.70% were occupied by males
• The Hepatic Encephalopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatic Encephalopathy pipeline products will significantly revolutionize the Hepatic Encephalopathy market dynamics.

Hepatic Encephalopathy Overview
Hepatic encephalopathy (HE) is a condition characterized by neurological abnormalities that occur as a complication of liver dysfunction or liver disease.

Get a Free sample for the Hepatic Encephalopathy Market Report:
https://www.delveinsight.com/report-store/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hepatic Encephalopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatic Encephalopathy Epidemiology Segmentation:
The Hepatic Encephalopathy market report proffers epidemiological analysis for the study period 2020-2032ain the 7MM segmented into:
• Total Prevalence of Hepatic Encephalopathy
• Prevalent Cases of Hepatic Encephalopathy by severity
• Gender-specific Prevalence of Hepatic Encephalopathy
• Diagnosed Cases of Episodic and Chronic Hepatic Encephalopathy

Download the report to understand which factors are driving Hepatic Encephalopathy epidemiology trends @ Hepatic Encephalopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hepatic Encephalopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatic Encephalopathy market or expected to get launched during the study period. The analysis covers Hepatic Encephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hepatic Encephalopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatic Encephalopathy Therapies and Key Companies
• Xifaxan (Rifaximin/OHE7): Salix Pharmaceuticals/Bausch Health
• Golexanolone: Umecrine Cognition AB
• Rifaximin (SSD): Salix Pharmaceuticals/Bausch Health
• AXA1665: Axcella Health
• GR3027 (Golexanolone): Umecrine Cognition
• VE303: Vedanta Biosciences
• Rifaximin: Bausch Health Americas, Inc.
• AST-120: Ocera Therapeutics
• HPN-100: Horizon Pharma
• MNK6106: Mallinckrodt

Discover more about therapies set to grab major Hepatic Encephalopathy market share @ Hepatic Encephalopathy Treatment Market
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hepatic Encephalopathy Market Drivers
• Increasing diagnosed prevalence of Hepatic Encephalopathy
• Emergence in novel treatment target
• Less competition among therapies

Hepatic Encephalopathy Market Barriers
• Adverse events associated with the current therapies
• The pipeline not very robust
• Disease burden
• Challenges in the diagnosis of disease

Scope of the Hepatic Encephalopathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hepatic Encephalopathy Companies: Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, Bausch Health Americas, Inc., Ocera Therapeutics, Horizon Pharma, Mallinckrodt, and others
• Key Hepatic Encephalopathy Therapies: Xifaxan (Rifaximin/OHE7), Golexanolone, Rifaximin (SSD), AXA1665, GR3027 (Golexanolone), VE303, Rifaximin, AST-120, HPN-100, MNK6106, and others
• Hepatic Encephalopathy Therapeutic Assessment: Hepatic Encephalopathy current marketed and Hepatic Encephalopathy emerging therapies
• Hepatic Encephalopathy Market Dynamics: Hepatic Encephalopathy market drivers and Hepatic Encephalopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hepatic Encephalopathy Unmet Needs, KOL's views, Analyst's views, Hepatic Encephalopathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.